Retatrutide vs Tirzepatide: Weight Loss Results Compared

Few topics in metabolic medicine generate as much curiosity as the comparison between retatrutide and tirzepatide. Both are injectable peptides studied for significant weight reduction, but they are at very different stages of development and work through different mechanisms. This guide walks through what the published trial data actually shows, where the two differ, and how to read the headline percentages without getting swept up in hype. This is educational information only — not medical advice, and not a recommendation to start, stop, or change any treatment.

The quick status check

Before comparing results, it's worth being clear about regulatory standing. Tirzepatide is an FDA-approved medication (marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management). It has completed large Phase 3 trials and has a well-characterized safety and efficacy profile.

Retatrutide, by contrast, is investigational. It is not FDA-approved as a finished drug, and at the time of writing it remains in clinical trials. Any use of retatrutide outside of a registered study would need to be discussed with — and supervised by — a licensed clinician. Early results are promising, but Phase 3 outcomes and long-term safety data are still being gathered. Keep that asymmetry in mind: you're comparing a finished, approved drug against a candidate that still has important questions to answer.

How the two drugs differ in mechanism

The difference in results starts with the difference in design:

• Tirzepatide is a dual agonist — it activates both the GIP and GLP-1 receptors. Those two incretin pathways work together to reduce appetite, slow gastric emptying, and improve how the body handles glucose.
• Retatrutide is a triple agonist — it targets GIP and GLP-1 plus the glucagon receptor. The added glucagon activity is thought to increase energy expenditure and influence fat metabolism, which may help explain the larger weight changes seen in early studies.

In short, retatrutide adds a third lever. More receptor activity isn't automatically "better" for every person — it can also shift the side-effect and monitoring picture — but it is the structural reason analysts expect larger average weight loss.

What the trial numbers show

The most-cited tirzepatide weight data comes from the SURMOUNT-1 trial in adults with obesity (without diabetes). Over 72 weeks, participants on the highest dose saw average body-weight reductions in the neighborhood of 20–22%, with lower doses producing proportionally smaller results. These are robust, peer-reviewed, Phase 3 figures.

Retatrutide's headline figures come from a Phase 2 trial published in 2023. Over 48 weeks, participants on the highest dose saw average reductions of roughly 24%, and the weight-loss curve had not clearly flattened by the end of the study — suggesting the plateau might come later. On the surface that edges past tirzepatide's numbers.

But the comparison deserves caveats. These were separate trials with different durations, different populations, and different protocols — not a head-to-head study. A 48-week Phase 2 result is not directly interchangeable with a 72-week Phase 3 result. Phase 2 trials are smaller and designed primarily to explore dosing and signals, so the retatrutide figures could shift once larger Phase 3 data arrives. Treat the "retatrutide wins by a few points" narrative as plausible but unconfirmed.

Side effects and tolerability

Both compounds share the GLP-1 class side-effect profile: nausea, diarrhea, constipation, and reduced appetite, most common during dose escalation. These effects are usually dose-dependent and tend to ease as the body adjusts. Because retatrutide adds glucagon-receptor activity, trials also watched for changes in heart rate and other metabolic markers. If you want a deeper breakdown of what's been reported, see our overview of retatrutide side effects. Slow, gradual titration is the common theme across both drugs for keeping side effects manageable.

Reading results responsibly

Average trial numbers describe a group, not an individual. Response varies widely from person to person based on starting weight, diet, activity, sleep, other medications, and how well someone tolerates escalation. "24% average" does not mean any given person will lose 24% — some lose more, some less. Weight regain after stopping is also a documented pattern across this drug class, which is why clinicians frame these as long-term tools rather than short courses.

If you're tracking a protocol under clinical supervision, consistency matters more than chasing the highest number. Tools like our dose tracker can help you log injections and note how you're feeling over time, and our calculator pages for retatrutide and tirzepatide exist to help you understand the math behind a prescribed plan — not to replace one. Any dosing decision belongs with a qualified prescriber who knows your full history.

The bottom line

On current evidence, retatrutide's early data suggests it may produce somewhat greater average weight loss than tirzepatide — but it's comparing an investigational Phase 2 candidate against an approved, Phase 3-validated drug. Tirzepatide has the advantage of regulatory approval, a mature safety record, and real-world availability. Retatrutide has intriguing mechanism and early numbers, with the important questions of long-term safety and confirmed efficacy still pending. If you're weighing options, the most useful next step is a conversation with a licensed clinician rather than a percentage on a chart.